Logotype for Shenzhen Mindray Bio-Medical Electronics Co Ltd

Mindray (300760) Q1 2025 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for Shenzhen Mindray Bio-Medical Electronics Co Ltd

Q1 2025 earnings summary

23 Jul, 2025

Executive summary

  • 2024FY revenue was 36.7 billion RMB, up 5.1% year-over-year, with net profit at 11.7 billion RMB, up 0.7%.

  • Net operating cash flow for 2024FY grew 12.4% to 12.4 billion RMB.

  • Q1 2025 revenue was 8.24 billion RMB, down 12.12% year-over-year; net profit was 2.63 billion RMB, down 16.81%.

  • International business in Q1 2025 grew nearly 5% year-over-year, with a two-year CAGR over 15%; international revenue share rose to 47%.

  • Domestic business in Q1 2025 declined over 20% year-over-year but increased more than 50% sequentially from Q4 2024.

Financial highlights

  • Gross margin for 2024FY was 63.1%, down 1.07 percentage points year-over-year.

  • Net margin for 2024FY was 31.77%, down 1.38 percentage points year-over-year.

  • Total assets at year-end 2024 were 56.6 billion RMB, up 18.2% year-over-year; at Q1 2025, assets reached 58.36 billion RMB, up 3.04% from year-end.

  • Operating cash flow in Q1 2025 was 1.49 billion RMB, down 47.83% year-over-year.

  • Basic and diluted EPS in Q1 2025 were RMB 2.1698, down over 16% year-over-year.

Outlook and guidance

  • Revenue in 2025 is expected to follow a pattern of a stronger second half, with a major growth turning point anticipated from Q3.

  • International business is expected to maintain rapid growth, especially in developing countries.

  • Domestic business is anticipated to rebound from Q3 2025 as equipment upgrades accelerate.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more